Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704944 | 0.93 | GAA (0.68) | GAASIGMAR1ALDH1A1TSHRALOX15 | |
| SCHEMBL13004984 | 0.92 | GAA (0.55) | GAASIGMAR1ALDH1A1KDM4ETSHR | |
| SCHEMBL18704948 | 0.91 | GAA (0.71) | GAASIGMAR1ALDH1A1TSHRALOX15 | |
| SCHEMBL18704941 | 0.86 | GAA (0.48) | GAASIGMAR1ALDH1A1KDM4ETDP1 | |
| SCHEMBL3767691 | 0.86 | GAA (0.48) | GAASIGMAR1ALDH1A1KDM4ETSHR | |
| SCHEMBL18289220 | 0.86 | GAA (0.48) | GAASIGMAR1ALDH1A1KDM4ETSHR | |
| SCHEMBL1911488 | 0.84 | ALOX15 (0.62) | GAASMN1; SMN2ALDH1A1KDM4ETDP1 | |
| SCHEMBL3774166 | 0.83 | KDM4E (0.56) | GAASMN1; SMN2RECQLALDH1A1KDM4E | |
| SCHEMBL25443837 | 0.82 | PKM (0.45) | GAASIGMAR1SMN1; SMN2RECQLALDH1A1 | |
| SCHEMBL25143945 | 0.82 | SIGMAR1 (0.46) | GAASIGMAR1ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9938294-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE HOLDINGS CORPORATION (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20100298329-A1 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | MASSACHUSETTE INSTITUTE OF TECHNOLOGY (US) | 2010-11-25 | — | — | US | disclosed |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | TIMMER RICHARD T | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
| US-20100298329-A1 | TOLPERISONE AND TOLPERISONE-LIKE DRUGS FOR THE TREATMENT OF K-RAS ASSOCIATED CANCERS | NRAS, KRAS, RASGRP1 | GAA 3839/4885SIGMAR1 3895/4885SMN1; SMN2 4882/4885 |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | GAA 2581/4885SIGMAR1 4728/4885SMN1; SMN2 3555/4885 |
| US-20070043051-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | GAA 852/4885SIGMAR1 3025/4885SMN1; SMN2 4172/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
| US-10174028-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
| US-20170210754-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | GAA 4721/4885SIGMAR1 4327/4885SMN1; SMN2 4604/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | GAA 2581/4885SIGMAR1 4728/4885SMN1; SMN2 3555/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | GAA 2581/4885SIGMAR1 4728/4885SMN1; SMN2 3555/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | GAA 244/4885SIGMAR1 3984/4885SMN1; SMN2 2713/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | GAA 2581/4885SIGMAR1 4728/4885SMN1; SMN2 3555/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | GAA 4404/4885SIGMAR1 2850/4885SMN1; SMN2 1821/4885 |
| US-10023570-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | GAA 2839/4885SIGMAR1 3943/4885SMN1; SMN2 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.